MX2021011224A - Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. - Google Patents

Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria.

Info

Publication number
MX2021011224A
MX2021011224A MX2021011224A MX2021011224A MX2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A
Authority
MX
Mexico
Prior art keywords
arterial hypertension
pulmonary arterial
treating
patient
apah
Prior art date
Application number
MX2021011224A
Other languages
English (en)
Spanish (es)
Inventor
Melissa Rhodes
Steve Wring
Thomas Pack
Julie Rurka
Magdalena Alonso-Galicia
David Carpenter
Original Assignee
Altavant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altavant Sciences Gmbh filed Critical Altavant Sciences Gmbh
Publication of MX2021011224A publication Critical patent/MX2021011224A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021011224A 2019-03-15 2020-03-13 Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. MX2021011224A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962819162P 2019-03-15 2019-03-15
PCT/IB2020/000177 WO2020188352A1 (en) 2019-03-15 2020-03-13 A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Publications (1)

Publication Number Publication Date
MX2021011224A true MX2021011224A (es) 2021-12-10

Family

ID=71092560

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011224A MX2021011224A (es) 2019-03-15 2020-03-13 Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria.

Country Status (9)

Country Link
US (2) US11576915B2 (cg-RX-API-DMAC7.html)
EP (1) EP3938043A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022525202A (cg-RX-API-DMAC7.html)
KR (1) KR20210139293A (cg-RX-API-DMAC7.html)
CN (1) CN113784717A (cg-RX-API-DMAC7.html)
AU (1) AU2020244278A1 (cg-RX-API-DMAC7.html)
CA (1) CA3133589A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021011224A (cg-RX-API-DMAC7.html)
WO (1) WO2020188352A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019382168A1 (en) * 2018-11-16 2021-06-03 Altavant Sciences Gmbh A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
CN113557022A (zh) * 2019-01-30 2021-10-26 阿尔塔万特科学公司 用罗达司他乙酯治疗肺动脉高压的给药方案和方法
CN113784717A (zh) 2019-03-15 2021-12-10 阿尔塔万特科学公司 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药
WO2023062595A1 (en) * 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101815534A (zh) * 2007-07-11 2010-08-25 莱西肯医药有限公司 用于治疗肺动脉高压以及相关疾病和病症的方法和组合物
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
US9399741B2 (en) 2013-10-09 2016-07-26 Uop Llc Methods and apparatuses for desulfurizing hydrocarbon streams
KR20210102887A (ko) * 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
AU2019382168A1 (en) * 2018-11-16 2021-06-03 Altavant Sciences Gmbh A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
US20200188398A1 (en) 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating sarcoidosis-associated pulmonary hypertension
WO2020128614A1 (en) 2018-12-17 2020-06-25 Altavant Sciences Gmbh Method for treating interstital lung disease
CN113557022A (zh) 2019-01-30 2021-10-26 阿尔塔万特科学公司 用罗达司他乙酯治疗肺动脉高压的给药方案和方法
CN113784717A (zh) 2019-03-15 2021-12-10 阿尔塔万特科学公司 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药

Also Published As

Publication number Publication date
WO2020188352A1 (en) 2020-09-24
US20200289510A1 (en) 2020-09-17
CA3133589A1 (en) 2020-09-24
EP3938043A1 (en) 2022-01-19
US11576915B2 (en) 2023-02-14
KR20210139293A (ko) 2021-11-22
US20240024316A1 (en) 2024-01-25
AU2020244278A1 (en) 2021-09-30
CN113784717A (zh) 2021-12-10
JP2022525202A (ja) 2022-05-11

Similar Documents

Publication Publication Date Title
MX2008013578A (es) Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
GB0423653D0 (en) Pharmaceutical compounds
CA2549801A1 (en) Use of treprostinil to improve kidney functions
ZA200500887B (en) Use of and some novel imidazopyridines.
WO2020157577A8 (en) A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl
WO2001039762A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MX2024014626A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton
WO2007149283B1 (en) Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
EP1594885B8 (de) Medikament zur wachstumsinhibierung von tumoren
CA3119909A1 (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
RU2015119377A (ru) Лекарственные формы леводопы для быстрого купирования болезни паркинсона
WO2020219645A3 (en) Methods for reducing the weight loss or increasing the weight of a feline in need thereof
MX2022006083A (es) Metodos para tratar afecciones relacionadas con el receptor s1p1.
MX2023012039A (es) Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos.
MX2022008342A (es) Metodos para tratar afecciones relacionadas con el receptor de s1p1.
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2024008803A (es) R-fadrozol para usar en el tratamiento de aldosteronismo.
WO2020128614A8 (en) Method for treating interstital lung disease
MX2025005154A (es) Formulaciones orales compactables de ibutamoren.
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2022040369A8 (en) Methods for treating remitting multiple sclerosis